A novel platform that uses naturally occurring vault protein nanocages to encapsulate sweet proteins, enhancing their resistance to heat, low pH, and long-term storage. This technology enables stable, scalable production of natural sweeteners like Brazzein, Monellin, and Thaumatin for food and beverage applications.
Natural sweet proteins such as Brazzein, Monellin, and Thaumatin offer intense sweetness with minimal calories, but their commercial use has been limited by poor stability under heat, acidic conditions, and extended storage. This technology addresses those challenges by encapsulating sweet proteins within vault protein nanocages, naturally occurring shell-like particles found in many eukaryotes including humans. Because vaults are biocompatible and naturally derived, they present minimal risk of allergenicity or regulatory complications. A yeast-based production system makes large-scale manufacturing economical and robust, positioning this approach as a practical pathway to bring stable, natural protein sweeteners to market.
Key features:
The underlying vault encapsulation platform and yeast-based production method have been validated in the principal investigator's laboratory using model enzymes, demonstrating clear stability improvements under heat, acidic pH, and extended storage conditions. The current proposal is a one-year proof-of-concept study to confirm that the same benefits transfer to commercially relevant sweet proteins. Planned validation includes thermostability assays at multiple temperatures, low-pH storage testing over nine months, and sensory evaluation by a taste panel. Upon successful completion, the technology will be positioned for pilot-scale trials and partnership with food and beverage companies seeking stable natural sweetener ingredients.
The University of Pittsburgh is a large, comprehensive public research university anchored in an urban innovation corridor with a strong translational focus. Integration with UPMC, a leading academic medical center, enables clinical studies, access to broad patient populations, and co-located clinical–engineering labs that shorten paths from discovery to deployment. A nearby research and technology district, extensive core facilities, and an engineering co-op program give companies entry points for prototyping and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DoD, and DOE. A dedicated technology transfer office provides IP strategy, licensing, startup support, and contracting for industry partners.